B+
Bull case
20%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-07-25 · RankAlpha Sentiment Codex
GALT
Galectin TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The FDA meeting provided meaningful regulatory clarity: Galectin reported alignment on the Phase 3 endpoint, central endoscopy review, single-dose design, and traditional approval route [#SEC-8K-2026-06-23]. NAVIGATE biomarker and liver-stiffness analyses provide additional biological support [#SEC-8K-2026-05-15].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -11.5.
What can break
Financing and partnering risk remains material despite the previously reported projected cash runway through April 2027 [#SEC-8K-2026-03-31].
Momentum
86
Value
41
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.20 · Bull $8.00 · Bear $1.50Analysis 2026-07-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $11.00
Why
Momentum86 · Δ7d +32.7
Value41 · Δ7d -0.0
Sentiment51 · Δ7d -11.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -11.5.
Contradictions & invalidation
- • Financing and partnering risk remains material despite the previously reported projected cash runway through April 2027 [#SEC-8K-2026-03-31].
- • Insider open-market sales after option exercise may add short-term supply and sentiment pressure [#SEC-FORM4-2026-06-30].
- • Belapectin still requires a future Phase 3 trial and traditional approval, with no announced partner.
Catalyst clock
2026-06-23
FDA Type C alignment de-risked the Phase 3 path [#SEC-8K-2026-06-23]
Lead driver: Sentiment · See AI snapshot
Momentum
86
9% active weight
Current posture
7d trendSoftening
Δ7d
+32.7
Δ21d
+74.2
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
51
62% active weight
Current posture
7d trendSoftening
Δ7d
-11.5
Δ21d
-34.6
Why this grade
Composite grade D. Momentum 86.5 / Value 41.2 / Sentiment 50.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-25. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$3.20
Analysis reference price unavailable
Analysis 2026-07-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-07-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$353.98M
Beta
1.01
Shares Out
100.85M
P/E (TTM) · Derived
-7.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-14.41
Rev YoY
-
EPS YoY
+16.6%
Gross Margin
-
Op Margin
-
Net Debt
$116.04M
Current Ratio
0.10
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data